Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name: CAPITELLO-281
What type of cancer is this for? Prostate
Phase: III
Who is this trial for? Men who have hormone sensitive prostate cancer (testosterone can be stopped or blocked to help prevent cancer growth) that has spread to other parts of the body.
What is National Clinical Trial #? : NCT04493853
Brief summary of trial: This trial is looking to see how well capivasertib and abiraterone work compared to a harmless medicine and abiraterone.
Need to know: Your tumor tissue must be PTEN negative. (PTEN stands for Phosphatase and TENsin homolog deleted on chromosome 10)
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: Evopar-Prostate
What type of cancer is this trial for? Patients with hormone resistant, metastatic castration-sensitive prostate cancer
What biomarkers are involved? None
National Clinical Trial # NCT06120491
Brief Summary of the trial: Patients with metastatic hormone-resistant and non-hormone resistant metastatic castration-sensitive prostate cancer, will receive physician’s choice of new hormonal agent in combination with either new drug AZD5305 vs. PLACEBO. This is a double-blinded study, which means neither patient nor provider will know whether patients are receiving AZD5305 drug or placebo.
Need to know information: These drugs are pills, not IV, and you may get placebo in combination with hormone agent.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
NAME: PanTumor 3- PROSTATE
What type of cancer is this for? Prostate
Phase: II
Who is this trial for? Men with advanced prostate cancer that may have spread to other parts of your body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see what drug combination works better to treat your prostate cancer.
Need to know: Your prostate cancer must be “castration-resistant”, which means that your cancer continues to grow even when your testosterone level is very low.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]